MGD024
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 90 patients (estimated)
- Sponsors
- MacroGenics
- Tags
- Bispecific Antibody, CD123, CD3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1691
- NCT Identifier
- NCT05362773
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.